Schroder Investment Management Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Schroder Investment Management Group’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.51M	Buy	+115,208	New	+$2.4M	﹤0.01%	883
2025 Q4	–	Sell	-123,404	Closed	-$1.92M	–	1207
2025 Q3	$1.92M	Buy	123,404 +1,241	+1%	+$16.2K	﹤0.01%	942
2025 Q2	$1.14M	Buy	122,163 +64,598	+112%	+$711K	﹤0.01%	982
2025 Q1	$759K	Hold	57,565	–	–	﹤0.01%	1032
2024 Q4	$721K	Hold	57,565	–	–	﹤0.01%	1054
2024 Q3	$1.09M	Buy	+57,565	New	+$1.19M	﹤0.01%	1021

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Schroder Investment Management Group's SNDX Position: Q2 2026 in Review

Schroder Investment Management Group opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 115,208 shares worth $2.51M. The stake represents ﹤0.01% of the portfolio and ranks #883 among its holdings. This is a return to the name: Schroder Investment Management Group previously reported a position in SNDX as recently as Q3 2025.

Schroder Investment Management Group first reported a position in SNDX in Q3 2024 and has held it in 6 quarters since. 152 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

Schroder Investment Management Group held 115,208 shares of Syndax Pharmaceuticals worth $2.51M as of Q2 2026.
Syndax Pharmaceuticals was a new Schroder Investment Management Group position in Q2 2026.
Syndax Pharmaceuticals made up ﹤0.01% of Schroder Investment Management Group's portfolio in Q2 2026, its #883 holding.
Schroder Investment Management Group first reported a position in Syndax Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
152 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.